LMAT stock forecast, quote, news & analysis

Key Takeaways

• LMAT shares traded in a narrow band around $78 to $84 over the past month, ending near $83 for a modest gain of roughly 5.7% over the trailing 30 days.
• Second-quarter 2026 organic revenue grew 10%, led by the Artegraft product line, which rose 34% and now represents about 21% of total sales.
• Gross margin expanded 210 basis points to 72.1%, while operating income climbed 26% to a record $20.4 million.
• Foreign-exchange pressure, Middle East export delays, and cardiac allograft supply constraints kept quarterly revenue slightly below management guidance.
• Full-year 2026 guidance implies roughly 12% reported sales growth and about 19% EPS growth at the midpoint.
• Analyst consensus remains "Buy," with an average 12-month price target near $107, well above the recent share price.

Current Market Snapshot

LeMaitre Vascular has traded with a defensive, grind-higher character in recent weeks, with shares hovering in the low-$80s after a mild pullback in early October. The stock's roughly 5.7% advance over the trailing 30 days reflects steady underlying demand rather than a single headline catalyst, consistent with the company's profile as a niche medical-device maker with durable pricing power. Against the backdrop of an aging population and rising rates of diabetes and peripheral artery disease, investors have treated LeMaitre as a relatively stable healthcare holding, even as its valuation trades at a premium to many broader medtech peers.

LeMaitre Vascular (LMAT) Business Overview and Competitive Position

LeMaitre Vascular, Inc. (Nasdaq: LMAT) is a Burlington, Massachusetts-based provider of devices, implants, and services used in open vascular surgery to treat peripheral vascular disease. The company's product portfolio spans biologic and vascular grafts, carotid shunts, patches, valvulotomes, embolectomy catheters, and phlebectomy devices, and it also processes and cryopreserves human tissue for implantation. Its single operating segment sells through a direct sales force and distributors across the Americas, EMEA, and Asia-Pacific.

LeMaitre's competitive edge lies in niche, low-competition product categories where it can sustain premium pricing and recurring, procedure-driven demand. The fastest-growing piece of the business is Artegraft, a bovine carotid artery graft approved in 56 countries that management is positioning as both its largest and fastest-growing product line. A strong balance sheet—roughly $376 million in cash and securities—provides flexibility for expansion, while a disciplined cost structure supports above-average operating margins.

Recent Developments Driving LMAT

The most significant recent update came with second-quarter 2026 results reported in early August. Revenue of $70.4 million rose 10% organically, and Artegraft sales grew 34%, with grafts, carotid shunts, and patches each posting records. Gross margin improved to 72.1%, and operating income reached a record $20.4 million, up 26% year over year, aided by headcount restraint and a favorable product mix.

However, results landed roughly $1.1 million below sales guidance, which management attributed in roughly equal parts to a stronger U.S. dollar, export disruptions tied to Middle East conflict, and constrained supply of cardiac allografts. The company has guided to about $276 million in full-year revenue, implying continued double-digit growth, while flagging that foreign exchange and allograft supply may remain headwinds through the second half.

On the analyst front, sentiment has been broadly constructive. The consensus rating stands at "Buy" with an average price target near $107, and several firms have raised targets through 2026. Still, views are not uniform: Wells Fargo maintains an Equal-Weight rating after lowering its target to $94, and Freedom Capital Markets carries a Hold rating with an $81 target, reflecting debate over how much future growth is already reflected in the valuation. The company has also continued returning capital through a $0.25 per share quarterly dividend.

Trending AI Robots

For traders and investors who want to complement fundamental research with data-driven signals, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section, helping users cut through the noise. The bots vary by strategy, timeframe, and performance metrics, so the page serves as a practical starting point for exploring automated approaches tailored to different market conditions. Exploring the featured robots can provide a useful, quantitative complement to a broader research process.

2026 Outlook and What Investors Should Watch

Several forward-looking drivers are likely to shape LeMaitre's trajectory through the remainder of 2026. The Artegraft international rollout remains central: management is targeting about $11 million in Artegraft sales for the year, up from $4 million in 2025, with plans to pursue major approvals in Korea, Brazil, and India in 2027 and longer graft packaging filings in the U.S. and Europe. Expansion of the sales force toward 170 to 180 representatives and a wider distribution footprint, including a tripled primary warehouse and new facilities in Europe, are intended to support that growth.

At the same time, investors should monitor the external factors that weighed on the second quarter. Currency movements, Middle East export logistics, and cardiac allograft supply will influence whether reported results track the company's organic growth momentum. Regulatory oversight also remains a watch item, following additional quality-system observations from a 2026 FDA re-audit that management is working to resolve. With the stock trading well below its average analyst target but at a premium valuation, execution on Artegraft, margin expansion, and the resolution of supply constraints will be key to sustaining investor confidence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations